Lupin (BOM:500257) Change In Inventory : ₹0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1995. Start your Free Trial

What is Lupin Change In Inventory?

Lupin's change in inventory for the quarter that ended in Mar. 2025 was ₹0 Mil. It means Lupin's inventory stayed the same from Dec. 2024 to Mar. 2025 .

Lupin's change in inventory for the fiscal year that ended in Mar. 2025 was ₹-5,412 Mil. It means Lupin's inventory increased by ₹5,412 Mil from Mar. 2024 to Mar. 2025 .

Lupin's Total Inventories for the quarter that ended in Mar. 2025 was ₹54,764 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lupin's Days Inventory for the quarter that ended in Mar. 2025 was 148.18.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lupin's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.62.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lupin's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.49.

Lupin Change In Inventory Historical Data

The historical data trend for Lupin's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Change In Inventory Chart

Lupin Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Change In Inventory

Get a 7-Day Free Trial

-6,574.20

-4,993.30

1,954.40

-4,401.50

-5,412.40

Lupin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Lupin Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Lupin (BOM:500257) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lupin's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	27381.75	/	16862	*	365 / 4
	=	148.18

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lupin's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	16862	/	27381.75
	=	0.62

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lupin's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	27381.75	/	55622
	=	0.49

Lupin Change In Inventory Related Terms

Thank you for viewing the detailed overview of Lupin's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Lupin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » Change In Inventory

Traded in Other Exchanges

LUPIN:India

Address

Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055

Website

https://www.lupin.com

Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines